Company
Hikma Pharmaceuticals PLC
OTCMKTS: HKMPF
Hikma Pharmaceuticals PLC is a pharmaceutical company engaged the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.
46 stories
Hikma Pharma slides on lower generics guidance
Revenue was flat at US$1.21bn in the first half, while operating profit slid 27% to US$239mln
Hikma Pharmaceuticals loses CEO
Siggi Olafsson has resigned from the post and from Hikma’s board of directors
Hikma Pharmaceuticals annual sales grow 9% but Generics guidance fails to meet expectations
“Looking at 2022, the business is well positioned to continue to grow, benefitting from our broad portfolio and pipeline, as well as our high-quality operations,” said chief executive Siggi Olafsson.
Hikma Pharmaceuticals to buy US generic sterile injectables producer Custopharm for US$375mln
The generics giant said the acquisition will complement its injectable product portfolio as well as enhancing its R&D operations
Hikma Pharmaceuticals first-half revenue and profits grow
“We are continuing to benefit from investments we have made to build our pipeline of new medicines," Siggi Olafsson said
Hikma Pharmaceuticals receives US approval for opioid overdose treatment Kloxxado
The firm also said current trading is in line with expectations and full-year outlook remains unchanged
Archive
FTSE 100 finishes flat as a pancake; Wall Street shakes off capital gains tax increase fears
London's leading index ended Friday at 6,939, more or less right where it ended Thursday
Hikma Pharmaceuticals revenue growth expectations come in below consensus
A City broker expects to see significant downgrades to consensus forecasts
Hikma Pharmaceuticals cuts 2020 guidance after delay in GSK knock-off approval
The firms received a minor complete response letter from the FDA and now has to address a “small number of questions”
Hikma hiked by Goldman Sachs on 'underappreciated' generic drugs arm
On top of three major generic drug launches in the next 18 months, the analysts see “optionality” from what is a complex generics portfolio
Hikma Pharma climbs after US court's generic drug ruling
Barclays upgraded its recommendation and hiked its share price target
Hikma Pharmaceuticals raises dividend as coronavirus drives injectables demand
The pharma group declared a dividend of US$0.16 per share, for the six months to June 30, 2020, up 14% on last year
Hikma Pharma upgraded to ‘overweight’ from ‘equal-weight’ by Morgan Stanley in note highlighting “hidden operating leverage”
The US investment bank's analysts said: “The profit contribution from the launch of gVascepa and gAdvair is not fully appreciated by the market, in our view"
Hikma Pharmaceuticals majority shareholder offloads entire stake
German competitor Boehringer Ingelheim is exiting its investment via a placing and a share buyback
Hikma Pharmaceuticals says generic Vascepa approved by US FDA
In London, Hikma shares rose by 38p or 1.51% to change hands at 2,551.49p.
Hikma sees pandemic-driven demand spike
The firm is to pay the final dividend and reiterated previous guidance for the full year
Hikma Pharmaceuticals upgraded to ‘overweight’ by JP Morgan after Vascepa litigation win
A US court this week ruled in favour of Hikma, which is developing a generic version of Amarin's Vascepa
Hikma wins litigation over heart disease prevention drug
The pharma company is developing a generic version of Vascepa, commercialised by Amarin
Hikma in nasal spray licence agreement, full-year profits soar
The firm said it is not experiencing disruption from the coronavirus outbreak while profits soared in 2019
Hikma hurt by JP Morgan downgrade to ‘underweight’
Analysts at the investment bank said headwinds at the generics division are “underappreciated”